Endpoints News
How FDA advisors voted on popular peptides Read in browser
Endpoints News
Thank you for reading, dupa dupackia!
basic
UPGRADE
M T W Th Fri
24 July, 2026
Endpoints 11 - Reserve Your Spot
The most differentiated science stays out of public view. This September, the Endpoints newsroom reveals the 11 private companies worth watching, live at the State Room in Boston. See the list first, reserve your spot and save with the early bird rate.
top stories
1. Amgen shares new analysis with FDA in bid to keep Tavneos on the market
2. Updated: FDA adcomm backs popular wellness peptides, despite staff concerns
3. CHMP recommends Minoryx’s ALD drug, rejects Zevra’s Meplyffa
4.
news briefing
Novo asks court to block Lilly ads; Merck strikes HIV PrEP deal
5. Sanofi nixes Kymab-originated OX40L antibody in eczema
6. Ipsen’s Bylvay fails key trial in children with rare liver disease
7.
peer review
Michael Ehlers joins Formation Bio to lead R&D; Black Diamond co-founder dies at 67
8.
in focus
Biogen’s Alzheimer’s data spur excitement, confusion about tau-targeting drugs
more stories
• 
Lydia Ramsey Pflanzer
.

We're on Day 2 of a marathon peptide advisory committee meeting. Shelby Livingston has been keeping track of the arguments presented, how the votes broke down, and what's ahead based on the recommendations of the group. Read the full coverage here.
.
Lydia Ramsey Pflanzer
Deputy Editor, Endpoints News
1
by Nicole DeFeudis

Am­gen shared a new analy­sis with the FDA that the com­pa­ny said sup­ports keep­ing its con­tro­ver­sial rare dis­ease drug Tavneos on the mar­ket.

The sub­mis­sion...

Read the full story
2
by Shelby Livingston

An FDA ad­vi­so­ry com­mit­tee vot­ed to rec­om­mend ex­pand­ing ac­cess to pop­u­lar pep­tides used by health and well­ness en­thu­si­asts for re­pair­ing mus­cles, heal­ing in­juries, boost­ing me­tab­o­lism...

Read the full story
Manufacturing Day 2026
A year into the tariff era, the biopharma industry has stopped bracing for impact — however manufacturing and supply chain leaders are still rewriting their plans on the fly. We’re bringing together the experts tracking what R&D logistics looks like today. Join us — find out what’s next.
3
by Anna Brown

Mi­no­ryx Ther­a­peu­tics fi­nal­ly scored back­ing from EU reg­u­la­tors for its neu­ro­log­i­cal drug that’s faced mul­ti­ple hur­dles. Mean­while, Zevra’s rare dis­ease drug got a set­back in...

Read the full story
News Briefing: Quick hits from the biopharma web
4
by ENDPOINTS

Plus news about Ab­b­vie and Gen­mab, John­son & John­son and Mannkind.

No­vo urges court to block Lil­ly’s GLP-1 ads: No­vo Nordisk asked a New Jer­sey...

Read the full story
5
by Elizabeth Cairns

Sanofi has de­cid­ed to stop work­ing on a drug for eczema it had hoped would be a suc­ces­sor to its im­muno­log­i­cal megablock­buster Dupix­ent.

The French...

Read the full story
6